While sequencing much larger cohorts containing more A3A_B carriers is required to confirm the potential involvement of A3H in cancer, it is noteworthy that the deletion of A3A and A3B from breast cancer cell lines greatly reduces but did not entirely eliminate the accrual of APOBEC signature mutations [59]. This evidence concerns the gene APOBEC3H and cancer.